A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126421 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Wenqiang Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: China State Institute of Pharmaceutical Industry, Pudong New Area, Shanghai 201203, China. Hauptthemen laut MEDLINE: Photochemotherapy, Porphobilinogen, Photosensitizing Agents, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of China, the Natural Science Foundation of Fujian Province, China, Natural Science Foundation of China.
Abstract (Originalsprache)
Photodynamic Therapy (PDT) is recognized for its exceptional effectiveness as a promising cancer treatment method. However, it is noted that overexposure to the dosage and sunlight in traditional PDT can result in damage to healthy tissues, due to the low tumor selectivity of currently available photosensitizers (PSs). To address this challenge, we introduce herein a new strategy where the small molecule-targeted agent, erlotinib, is integrated into a boron dipyrromethene (BODIPY)-based PS to form conjugate 6 to enhance the precision of PDT. This conjugate demonstrates optical absorption, fluorescence emission, and singlet oxygen generation efficiency comparable to the reference compound 7, which lacks erlotinib. In vitro studies reveal that, after internalization, conjugate 6 predominantly accumulates in the lysosomes of HepG2 cells, exhibiting significant photocytotoxicity with an IC50 value of 3.01 µM. A distinct preference for HepG2 cells over HELF cells is observed with conjugate 6 but not with compound 7. In vivo experiments further confirm that conjugate 6 has a specific affinity for tumor tissues, and the combination treatment of conjugate 6 with laser illumination can effectively eradicate H22 tumors in mice with outstanding biosafety. This study presents a novel and potential PS for achieving precise PDT against cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China State Institute of Pharmaceutical Industry, Pudong New Area, Shanghai 201203, China.
- Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry, Fuzhou University, Fuzhou 350108, China.
- State Key Laboratory of Photocatalysis on Energy and Environment & National & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, College of Chemistry, Fuzhou University, Fuzhou 350108, Chin…
ORCID-Profile: Jianyong Liu
Förderung
- the Natural Science Foundation of China
- the Natural Science Foundation of Fujian Province, China
- Natural Science Foundation of China
- Natural Science Foundation of Fujian Province, China
Zitieren
APA
Wu, W., Luo, C., Zhu, C., Cai, Z., & Liu, J. (2024). A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126421
Vancouver
Wu W, Luo C, Zhu C, Cai Z, Liu J. A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126421
BibTeX
@article{Wu2024,
author = {Wu, Wenqiang and Luo, Chengmiao and Zhu, Chunhui and Cai, Zhengyan and Liu, Jianyong},
title = {A Novel Boron Dipyrromethene-Erlotinib Conjugate for Precise Photodynamic Therapy against Liver Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126421}
}
EUVIMED